Journal of Psoriasis and Psoriatic Arthritis®
This journal is a member of the Committee on Publication Ethics (COPE).
Journal CME
Accreditation: The National Psoriasis Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation: The National Psoriasis Foundation designates each Journal CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
How to Claim Credit
Journal articles that are designated for CME credit will provide learners with a link to the accreditation information at the end of the article just before the reference list.
Manuscript Review CME
The National Psoriasis Foundation provides AMA PRA Category 1 Credits™ for reviewing manuscripts. A reviewer must meet the requirements of the ACCME for manuscript review in order to be awarded credit.
Accreditation: The National Psoriasis Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation: The National Psoriasis Foundation designates each manuscript review for a maximum of 3.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Manuscript reviews are reported by the Journal Administrator to the National Psoriasis Foundation on an annual basis. The National Psoriasis Foundation then contacts reviewers related to accreditation information and CME credit. For questions related to Manuscript Review, please email medicalaffairs@psoriasis.org.
Submit your manuscript today at https://mc.manuscriptcentral.com/jppa
The Journal of Psoriasis and Psoriatic Arthritis (JPPA) is a quarterly, peer-reviewed, specialty journal published by the National Psoriasis Foundation (NPF). The journal disseminates the latest clinical, translational, and basic research and practical treatment information about psoriasis, psoriatic arthritis, as well as related comorbidities and conditions. The goal of the JPPA is to provide readers with knowledge that advances their expertise, a goal accomplished by publishing evidence-based research.
Article Types:
JPPA publishes original research, review articles, case studies, commentary, and brief reports on all aspects of psoriatic disease including basic research, evaluation and diagnosis, heredity, pharmacotherapy, and symptom management.
Diversity, Equity, and Inclusion:
Psoriatic disease doesn’t discriminate. NPF advocates for improved access to care and meaningful access to treatments for all. JPPA is passionate about supporting diversity, equity, and inclusion in wider society through our publishing activities, which include ensuring diversity (ethnic and gender) in our editorial board, peer reviewers, and author base.
| George Han, MD, PhD | Icahn School of Medicine at Mount Sinai, New York, NY; Elmhurst Hospital Center, Queens, NY, USA |
| Alice B. Gottlieb, MD, PhD | University of Texas Southwestern Medical Center, Dallas, Texas, USA |
| John Y. M. Koo, MD | University of California-San Francisco Medical Center, San Francisco, CA, USA |
| Mark Lebwohl, MD | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| Andy Blauvelt, MD, MBA | Blauvelt Consulting, LLC, Annapolis, MD, USA |
| Jeffrey M. Cohen, M.D. | Yale School of Medicine, USA |
| Mona Shahriari, MD, FAAD | Yale University, New Haven, CT; Central CT Dermatology, Cromwell, CT, USA |
| Eingun James Song, MD, FAAD, Co-CMO | American Academy of Dermatology, Rosemont, IL, USA |
| Lakshi Aldredge, MSN, ANP-C | VA Portland Health Care System, Portland, OR, USA |
| Herve Bachelez, MD, PhD | Hôpital Saint-Louis Sorbonne Paris Cité, Université Paris Diderot, Paris, France |
| Jerry Bagel, MD | Psoriasis Treatment Center of Central New Jersey, East Windsor, NJ, USA |
| Luca Bianchi, MD | University of Rome Tor Vergata, Rome, Italy |
| David R. Bickers, MD | Columbia University Medical Center, New York, NY, USA |
| Robert Bissonnette, MD | University of Montreal Hospital Centre, Montreal, Canada |
| Erin Boh, MD, PhD | Tulane University School of Medicine, New Orleans, LA, USA |
| Anne M. Bowcock, PhD | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| Jeffrey P. Callen, MD | University of Louisville, Louisville, KY, USA |
| Vinod Chandran, MBBS, MD, DM, PhD | University of Toronto, Department of Medicine, Division of Rheumatology, Toronto Western Hospital, Toronto, ON, Canada |
| Robin Christensen, BSc, MSc, PhD | The Parker Institute, Copenhagen, Denmark |
| Kelly Cordoro, MD | University of California, San Francisco, CA, USA |
| Jeffrey Crowley, MD | Bakersfield Dermatology, Bakersfield, CA, USA |
| Kristina Callis Duffin, MD | The University of Utah, Salt Lake City, UT, USA |
| Lawrence Eichenfield, MD | University of California, San Diego, CA, USA |
| Charles N. Ellis, MD | University of Michigan Medical School, Ann Arbor, MI, USA |
| Steven Feldman, MD, PhD | Wake Forest Baptist Medical Center, Winston-Salem, NC, USA |
| Hassan Galadari, MD | College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates |
| Joel Gelfand, MD, MSCE | University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA |
| Dafna D. Gladman, MD | University of Toronto; Krembil Research Institute; Centre for Prognosis Studies in Rheumatic Diseases, University Health Network, Toronto Western Hospital, Toronto, Canada |
| Kenneth Gordon, MD | Medical College of Wisconsin, Milwaukee, WI, USA |
| Chris Griffiths, MB, MD | University of Manchester, Manchester, UK |
| Percio Gulko, MD | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| Philip Helliwell, MD | University of Leeds, Leeds, UK |
| Sylvia Hsu, MD | Baylor College of Medicine Houston, Houston, TX, USA |
| Abby Jacobson, MS, PA-C | Delaware Valley Dermatology Group, LLC, Wilmington, DE, USA |
| Joseph L. Jorizzo, MD | Wake Forest University School of Medicine, Winston-Salem, NC, USA; Weill Cornell Medical College, New York, NY, USA |
| Arthur Kavanaugh, MD | University of California, San Diego, CA, USA |
| Neil Korman, MD, PhD | University Hospitals Cleveland Medical Center, Cleveland, OH, USA |
| Gerald G. Krueger, MD | University of Utah School of Medicine, Salt Lake City, UT, USA |
| Richard Langley, MD | Dalhousie University, Halifax, NS, Canada |
| Thomas McCormick, PhD | Case Western Reserve University, Cleveland, OH, USA |
| Philip Mease, MD | University of Washington, Seattle, WA, USA |
| Nehal N. Mehta, MD, MSCE | National Heart, Lung and Blood Institute, Bethesda, MD, USA |
| Luigi Naldi, MD | Hospital San Bortolo, Vicenza, Italy |
| Amy Paller, MD | Northwestern University, Chicago, IL, USA |
| Kim Papp, MD, PhD | Probity Medical Research, Inc., Ontario, Canada |
| Lourdes M. Perez-Chada, MD, MMSc | International Dermatology Outcome Measures (IDEOM) Research Fellow; Psoriasis and Psoriatic Arthritis Clinical Research Fellow; Brigham and Women's Hospital-Harvard Medical School, Boston, MA, USA |
| Jörg Prinz, MD | Ludwig Maximilian University, Munich, Germany |
| Ronald Prussick, MD | George Washington University, Washington D.C., USA |
| Lluís Puig, MD, PhD | Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain |
| Abrar Qureshi, MD, MPH | Brown University, Providence, RI, USA |
| Kristian Reich, MD, PhD | Dermatologikum Hamburg, Hamburg, Germany |
| Cheryl Rosen, MD, FRCPC | University of Toronto, Toronto, Canada |
| David Rosmarin, MD | Tufts Medical Center, Boston, MA, USA |
| Eric Ruderman, MD | Northwestern Feinberg School of Medicine, Chicago, IL, USA |
| Caitriona Ryan, MD, FAAD | St. Vincent's University Hospital, Blackrock Clinic, Dublin, Ireland |
| Enrique Soriano, MD, MS | Hospital Italiano de Buenos Aires, Buenos Aires, Argentina |
| Mona Ståhle, MD, PhD | Karolinska Institutet, Stockholm, Sweden |
| Stephen Stone, MD, FAAD | SIU Medicine, Springfield, IL, USA |
| Paul Tebbey, PhD, MBA | AbbVie, Chicago, IL, USA |
| Abby Van Voorhees, MD | Eastern Virginia Medical School, Norfolk, VA, USA |
| John E. Wolf Jr., MA, MD | Baylor College of Medicine, Houston, TX, USA |
| Jashin J. Wu, MD | Dermatology Research and Education Foundation, Irvine, CA, USA |
| Melodie Young, MSN, ANP-C | Modern Dermatology and Modern Research Associates, Dallas, TX, USA |
Please read the guidelines below, then visit the submission site for Journal of Psoriasis and Psoriatic Arthritis (JPPA) at https://mc.manuscriptcentral.com/JPPA to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned.
Only manuscripts of sufficient quality that meet the aims and scope of the Journal will be reviewed.
As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.
- Article Types
- Editorial Policies
2.1 Peer Review Policy
2.2 Authorship
2.3 Acknowledgements
2.3.1 Writing Assistance
2.4 Funding
2.5 Declaration of Conflicting Interests
2.6 Research Ethics and Patient Consent
2.7 Clinical Trials
2.8 Reporting Guidelines
2.9 Data - Publishing Policies
3.1 Publication Ethics
3.1.1 Plagiarism
3.2 Contributor's Publishing Agreement
3.3 Open Access and Author Archiving
3.4 Permissions - Preparing your Manuscript
4.1 Formatting
4.2 Artwork, Figures and Other Graphics
4.3 Supplementary Material
4.4 Journal Layout
4.5 Reference Style
4.6 English Language Editing Services - Submitting your Manuscript
5.1 How to Submit your Manuscript
5.2 Title, Keywords and Abstracts
5.3 Corresponding Author Contact Details - On Acceptance and Publication
6.1 SAGE Production
6.2 Access to your Published Article - Further Information
Manuscripts submitted to the Journal of Psoriasis and Psoriatic Arthritis should be of general interest to researchers and medical professionals specializing in psoriatic disease research and patient care. Articles are typically 900 to 3,000 words long, but longer articles will be considered.
Reports of Original Research
Original, in-depth clinical and investigative laboratory research papers focused on the fundamental cause and treatment of psoriatic diseases.
Reviews
Reviews of literature, clinical trials, or patterns appearing in cases of psoriasis and psoriatic arthritis pertinent to factors such as the cause, diagnosis, prognosis, or therapy of these diseases.
Practical Therapeutics
In-depth review of a therapeutic modality or treatment procedure for the treatment of psoriasis or psoriatic arthritis.
Brief Reports and Abstracts
Brief clinical observations, reports of studies, or evaluations that are unique to the care of psoriasis or psoriatic arthritis.
Case Reports
Brief individual cases of psoriasis or psoriasis treatment of unusual interest.
Editorials and Commentaries
Brief, provocative, opinionated communications on issues pertinent to the treatment and care of psoriasis or psoriatic arthritis.
Journal of Psoriasis and Psoriatic Arthritis is a peer-reviewed specialty journal published by the National Psoriasis Foundation for its professional members and for dermatology and rheumatology specialists. The purpose of the journal is to provide the latest research and practical treatment information about psoriasis and psoriatic arthritis in a concise and easy-to-read format. Medical professionals are invited to submit articles to be considered for publication. JPPA recommends that authors follow the Uniform Requirements for Manuscripts Submitted to Biomedical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).Manuscripts selected for publication will be published in the print and online version of the Journal.
DISCLAIMER: The National Psoriasis Foundation is a 501(c)(3) lay, patient-driven nonprofit organization with a mission to drive efforts to cure psoriatic disease and improve the lives of those affected. Opinions expressed in this publication are those of the author(s) and do not necessarily reflect the view of the National Psoriasis Foundation, its Board of Directors, or its Medical Board. Only original articles will be considered for publication in JPPA. Please do not submit articles that are being submitted to other journals.
JPPA operates a conventional single-blind reviewing policy in which the reviewer’s name is always concealed from the submitting author.
The editorial staff will review the manuscript and, if it meets JPPA’s editorial standards, will send it to at least two reviewers. Reviewers will pay particular attention to scientific accuracy, relevance, novelty, importance, appropriate style, and whether the article would be of general interest to medical professionals and researchers focused on psoriasis or psoriatic arthritis. Decisions on manuscripts will be made as rapidly as possible.
Some degree of manuscript revision should be expected and regarded as constructive. A request to submit a revised manuscript does not guarantee that it will be accepted; rather this means only that it will be reconsidered, perhaps after additional peer review. The final editorial decision rests not only on the validity of the report and the opinions of the reviewers, but also on the editors’ judgment of the article’s novelty, clarity, importance, and likely degree of interest to the readership.
Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.
The list of authors should include all those who can legitimately claim authorship. This is all those who:
- Made a substantial contribution to the concept and design, acquisition of data or analysis and interpretation of data,
- Drafted the article or revised it critically for important intellectual content,
- Approved the version to be published.
Authors should meet the conditions of all of the points above. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.
One author should be designated as the corresponding author, with that author’s complete address, telephone and fax numbers, and e-mail address provided on the title page. The JPPA editor will correspond only with the corresponding author.
When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.
Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section.
Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.
All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.
Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.
Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance).
It is not necessary to disclose use of language polishing services.
The Journal requires all authors to acknowledge their funding in a consistent fashion under a separate heading. Please visit the Funding Acknowledgements page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
2.5 Declaration of Conflicting Interests
It is the policy of JPPA to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.
The Journal requires all authors to acknowledge all funding sources that supported their work as well as all institutional or corporate affiliations of the authors. These include but are not limited to employment, royalties, consulting arrangements with a commercial entity, stock or other equity ownership, stock options, patent licensing arrangements, payments for conducting or publicizing a product or study, or consulting relationships with investment companies. In addition, authors are required to disclose similar associations with companies that make a competing product.
Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’.
The Editors also require the reviewer to disclose any competing interests or conflicts of interest that might interfere with their objectivity (or to recuse oneself from acting as a reviewer). The Editors and members of the editorial staff have registered their competing interests with the National Psoriasis Foundation. The Editors and members of the editorial staff will ensure that all conflicts are appropriately resolved. Conflicts that cannot be appropriately resolved will result in rejection of the manuscript or review. Undisclosed conflicts may result in sanctions.
For guidance on conflict of interest statements, please see the ICMJE recommendations here.
2.6 Research Ethics and Patient Consent
Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki.
Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number. A copy of the IRB approval letter must be included with the submission or sent to the JPPA editor under separate cover.
For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal. If applicable, IRB approval must be mentioned in the methods section of all manuscripts. If the methods section is not sufficiently clear, authors may be asked to provide the editors with a copy of IRB-approved research protocols for the use of our reviewers.
Patients must not be identified by name or initials; numbers should be used. No other information, including clinical photos or family trees from which a patient could be identified, is permitted unless express written permission from the patient or family is provided at the time of manuscript submission.
Special Requirements for Studies Involving Animal Subjects
All research submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted. The journal has adopted the Consensus Author Guidelines on Animal Ethics and Welfare for Veterinary Journals published by the International Association of Veterinary Editors.
JPPA conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.
The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed Consolidated Standards of Reporting Trials (CONSORT) flow chart as a cited figure, and a completed CONSORT checklist as a supplementary file.
Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives.
SAGE acknowledges the importance of research data availability as an integral part of the research and verification process for academic journal articles.
JPPA requests all authors submit any primary data used in their research articles alongside their article submissions to be published in the online version of the journal, or provide detailed information in their articles on how the data can be obtained. This information should include links to third-party data repositories or detailed contact information for third-party data sources. Data available only on an author-maintained website will need to be loaded onto either the journal’s platform or a third-party platform to ensure continuing accessibility. Examples of data types include but are not limited to statistical data files, replication code, text files, audio files, images, videos, appendices, and additional charts and graphs necessary to understand the original research. The editors can also grant exceptions for data that cannot legally or ethically be released. All data submitted should comply with Institutional or Ethical Review Board requirements and applicable government regulations. For further information, please contact the editorial office at jppa@psoriasis.org.
SAGE is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the SAGE Author Gateway.
JPPA and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of articles published in the journal. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked using duplication-checking software. Where an article is found to have plagiarised other work or included third-party copyright material without permission or with insufficient acknowledgement, or where authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article (removing it from the journal); taking up the matter with the head of department or dean of the author’s institution and/or relevant academic bodies or societies; banning the author from publication in the journal or all SAGE journals, or appropriate legal action.
3.2 Contributor's Publishing Agreement
Before publication, SAGE requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. SAGE’s Journal Contributor’s Publishing Agreement is an exclusive licence agreement which means that the author retains copyright in the work but grants SAGE the sole and exclusive right and licence to publish for the full legal term of copyright. Exceptions may exist where an assignment of copyright is required or preferred by a proprietor other than SAGE. In this case copyright in the work will be assigned from the author to the society. For more information please visit our Frequently Asked Questions on the SAGE Journal Author Gateway.
3.3 Open Access and Author Archiving
JPPA offers optional open access publishing via the SAGE Choice program. For more information, please visit the SAGE Choice website. For information on funding body compliance, and depositing your article in repositories, please visit SAGE Publishing Policies on our Journal Author Gateway.
Authors are responsible for obtaining permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please visit our Frequently Asked Questions on the SAGE Journal Author Gateway.
Preferred formats for the text and tables of your manuscript are Word DOC, RTF, XLS. Please line-number all manuscripts. Manuscripts must be typed, double-spaced, with 1-inch or larger margins throughout, including title page, text, references, legends for illustrations, and tables. Text should be standard 10 or 12 point. Word templates are available on the Manuscript Submission Guidelines page of our Author Gateway.
4.2 Artwork, Figures and Other Graphics
For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit SAGE’s Manuscript Submission Guidelines.
Figures supplied in color will appear in color online regardless of whether or not these illustrations are reproduced in color in the printed version. For specifically requested color reproduction in print, you will receive information regarding the costs from SAGE after receipt of your accepted article.
The National Psoriasis Foundation encourages authors to submit relevant graphic elements, such as photographs, charts, tables, and illustrations. Authors are responsible for seeking permission to republish above-named graphic elements that have been previously published.
This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images, etc.) alongside the full-text of the article. These will be subjected to peer-review alongside the article. For more information please refer to our guidelines on submitting supplementary files, which can be found within our Manuscript Submission Guidelines page.
JPPA conforms to the AMA Manual of Style. Please also follow the instructions below.
Title Page
The title page shall include: (1) the title, (2) authors’ names, (3) authors’ highest earned academic degrees, (4) institutional affiliations and locations, (5) corresponding author information, (6) statement of funding sources and any authors’ conflicts of interest and, (7) word count, figure count, and number of references.
Abstract
All articles must be accompanied by an abstract not exceeding 250 words. The abstract should concisely summarize the major points and purpose of the manuscript and its key conclusions. The abstract should be structured into sections: Background, Objective, Methods, Results, and Conclusion. The abstract should not contain any references.
Key Words
A list of five to eight key words should appear after the abstract.
Abbreviations and Acronyms
Only standard abbreviations are to be used. Consult the Manual of Style by the American Medical Association. Abbreviations in the title are not acceptable, and they should be avoided in the abstract. A laboratory or chemical term or a disease process must be spelled out on first reference, with the acronym or abbreviation following in parentheses. The abbreviation or acronym should be used thereafter except in headlines.
Abbreviations must be limited primarily to those in general usage. Weights and measurements must be expressed in metric units. Temperatures must be expressed in degrees centigrade.
Artwork Guidelines
Illustrations, pictures and graphs, should be supplied with the highest quality and in an electronic format that helps us to publish your article in the best way possible. Please follow the guidelines below to enable us to prepare your artwork for the printed issue as well as the online version.
- Format: TIFF, JPEG: Common format for pictures (containing no text or graphs).
EPS: Preferred format for graphs and line art (retains quality when enlarging/zooming in). - Placement: Figures/charts and tables created in MS Word should be included in the main text rather than at the end of the document.
Figures and other files created outside Word (i.e. Excel, PowerPoint, JPG, TIFF, EPS, and PDF) should be submitted separately. Please add a placeholder note in the running text (i.e. “[insert Figure 1.]") - Resolution: Rasterized based files (i.e. with .tiff or .jpeg extension) require a resolution of at least 300 dpi (dots per inch). Line art should be supplied with a minimum resolution of 800 dpi.
- Color: Please note that images supplied in color will be published in color online and black and white in print (unless otherwise arranged). Therefore, it is important that you supply images that are comprehensible in black and white as well (i.e. by using color with a distinctive pattern or dotted lines). The captions should reflect this by not using words indicating color.
- Dimension: Check that the artworks supplied match or exceed the dimensions of the journal. Images cannot be scaled up after origination
- Fonts: The lettering used in the artwork should not vary too much in size and type (usually sans serif font as a default).
Figures and Tables
Manuscripts should contain no more than five total figures and tables. Additional figures and tables may be included in a supplement for web-only publication.
Tables may be included in the body of text in a Word document. They should be numbered consecutively (i.e., 1, 2, 3).
Tables must be editable as they will be styled to match the JPPA brand. Tables created in Microsoft Word or Excel are acceptable editable formats.
Figures must be submitted in electronic format. Figures must be cited in the text and numbered in order of mention. Figures must be numbered consecutively (i.e., 1, 2, 3). Multi-part figures must be marked clearly (e.g., 1A, 1B, 1C). They must be created with vector software such as Adobe Illustrator. Preferably, figures should be attached as separate documents, in addition to embedding them into Word documents. Please include file extensions when naming and saving files.
JPPA adheres to the AMA reference style. Please review the AMA guidelines to ensure your manuscript conforms to this reference style.
Try to limit references to those that are essential or most relevant. Number references in the order they appear in the text. In text, tables, and legends, indicate references with superscript Arabic numerals. When listing references, abbreviate names of journals according to Index Medicus. Please include full page range. Questions about references should be addressed to jppa@psoriasis.org.
List the first six authors; when there are more than six authors, list the first three authors followed by et al. Do not list only the first author followed by et al.
Manuscripts should contain no more than 75 references. Additional references may be included in a supplement for web-only publication.
4.6 English Language Editing Services
Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using SAGE Language Services. Visit SAGE Language Services on our Journal Author Gateway for further information.
5.1 How to Submit your Manuscript
JPPA is hosted on SAGE Track, a web based online submission and peer review system powered by ScholarOne™ Manuscripts. Visit https://mc.manuscriptcentral.com/JPPA to login and submit your article online.
IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created. For further guidance on submitting your manuscript online please visit ScholarOne Online Help.
5.2 Title, Keywords and Abstracts
Please supply a title, short title, an abstract and keywords to accompany your article. The title, keywords and abstract are key to ensuring readers find your article online through online search engines such as Google. Please refer to the information and guidance on how best to title your article, write your abstract and select your keywords by visiting the SAGE Journal Author Gateway for guidelines on How to Help Readers Find Your Article Online.
5.3 Corresponding Author Contact Details
Provide full contact details for the corresponding author including email, mailing address and telephone numbers. Academic affiliations are required for all co-authors. These details should be presented separately to the main text of the article to facilitate anonymous peer review.
6. On Acceptance and Publication
Your SAGE Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will be sent by PDF to the corresponding author and should be returned promptly.
6.2 Access to your Published Article
SAGE provides authors with online access to their final article.
Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the JPPA editorial office: jppa@psoriasis.org.